• Steven B Greenberg, Noah Ben-Isvy, Hyde Russell, Hannah Whitney, Chi Wang, and Mohammed Minhaj.
• NorthShore University, HealthSystem, Evanston, IL; University of Chicago, Pritzker School of Medicine, Chicago, IL. Electronic address: sgreenberg@northsshore.org.
• J. Cardiothorac. Vasc. Anesth. 2023 Aug 1; 37 (8): 141014171410-1417.

ObjectivesTo compare the number of eligible urgent and elective cardiac surgical patients who could be extubated successfully within 6 hours of surgery and who received sugammadex versus those who did not.DesignThis retrospective pilot study compared outcomes in cardiac surgical patients undergoing cardiopulmonary bypass between 2018 to 2021 who received sugammadex versus those who did not.SettingAt a tertiary-care hospital in the Northshore of Chicago.ParticipantsA total of 358 elective or urgent cardiac surgical patients who underwent cardiopulmonary bypass (by 1 cardiac surgeon) and were extubated within 24 hours of the end of surgery at Evanston Hospital in Evanston, IL, were included.InterventionsData were examined in the following 2 groups of patients: those who were administered sugammadex and those who were not.Measurements And Main ResultsAfter performing propensity matching for age, sex, body mass index, kidney or liver disease, the number of preoperative conditions (defined as the sum of the presence of the following medical conditions: diabetes, immunosuppressive disease, on home oxygen, on inhaled bronchodilator, or sleep apnea), number of patients who underwent elective or urgent surgery in each group, surgery time, cardiopulmonary bypass duration, number of intraoperative blood products, use of intraoperative midazolam and propofol, a statistically significant increase in the percentage of patients in the sugammadex group were extubated within 6 hours of the end of surgery versus those who did not receive sugammadex (96.67% v 81.33%, p = 0.0428). In addition, there was a statistically significant reduction in time to extubation (hours) (4.72 ± 2.92) v (3.57± 1.96 p = 0.0098) in the sugammadex group. All other outcomes did not meet statistical significance.ConclusionThis retrospective study suggested that using sugammadex reversal in cardiac surgical patients undergoing cardiopulmonary bypass may result in more patients meeting the Society of Thoracic Surgery benchmark extubation criteria within 6 hours of the end of surgery.Copyright © 2023 Elsevier Inc. All rights reserved.

12 keywords...

hide…